Kimitoshi Kubo

Kimitoshi Kubo

Auto-generated profile, based on publicly available information

Kimitoshi Kubo

Department of Gastroenterology National Hospital Organization Hakodate Medical Center Hakodate Hokkaido Japan

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
KKKimitoshi Kubo
Kimitoshi Kubo
MKMototsugu Kato
Mototsugu Kato
KMKatsuhiro Mabe
Katsuhiro Mabe

23 October 2014 in Journal of Hepato-Biliary-Pancreatic Sciences
Verified
Journal Article
Closed access
PDF file
KKKazumichi Kawakubo
Kazumichi Kawakubo
HKHiroshi Kawakami
Hiroshi Kawakami
Masaki KuwataniMasaki Kuwatani
Masaki Kuwatani
TKTaiki Kudo
Taiki Kudo
YAYoko Abe
Yoko Abe
NSNaoya Sakamoto
Naoya Sakamoto

20 October 2022 in Helicobacter
Verified
Journal Article
Open access
MTMomoko Tsuda
Momoko Tsuda
YWYoshiyuki Watanabe
Yoshiyuki Watanabe
RORitsuko Oikawa
Ritsuko Oikawa
RWRyosuke Watanabe
Ryosuke Watanabe
MHMasayuki Higashino
Masayuki Higashino
MKMototsugu Kato
Mototsugu Kato
Background: Although there are many Helicobacter pylori (H. pylori) diagnostic methods, the culture and antibiotic susceptibility test is an important method for selecting the most effective H. pylori eradication regimen. However, this diagnostic method is complicated and takes several days; therefore, the development of a rapid and simple diagnostic method is required. Eradication failure due to clarithromycin (CAM) resistance should also be considered. In this study, we report the clinical evaluation of point‐of‐care testing (POCT) kit using intragastric fluid, a novel kit for detecting H. pylori and CAM resistance.Materials and Methods: The study participants were 143 patients suspected of H. pylori infection and had an endoscopic examination. The novel diagnostic kit diagnosed H. pylori infection and CAM resistance‐associated mutation using intragastric fluid. To diagnose H. pylori infection, the relationship between the diagnostic kit and conventional diagnostic methods (urea breath test, stool antigen test, culture test, and real‐time polymerase chain reaction [PCR]) was evaluated. For CAM resistance‐associated mutation detection, the concordance between the diagnostic kit and antibiotic susceptibility test was evaluated.Results: The diagnosis of H. pylori infection with the novel molecular diagnostic kit using intragastric fluid showed significant relationship with conventional diagnostic methods. Especially when the culture was control, the sensitivity was 100% (67/67), the specificity was 95.9% (71/74), and the overall concordance was 97.9% (138/141). The detection of CAM resistance‐associated mutations had a concordance rate of 97.0% (65/67) when compared with the antibiotic susceptibility test.Conclusions: The H. pylori molecular POCT kit uses intragastric fluid as a sample and can diagnose H. pylori infection and detect CAM resistance‐associated mutations within an hour. This novel kit is expected to prove useful in selecting the most effective eradication regimen for H. pylori.

10 September 2019 in Digestion
Verified
Journal Article
Closed access
PDF file
KKKimitoshi Kubo
Kimitoshi Kubo
MKMototsugu Kato
Mototsugu Kato
KMKatsuhiro Mabe
Katsuhiro Mabe
NHNaohiko Harada
Naohiko Harada
YIYoichiro Iboshi
Yoichiro Iboshi
TAToraji Amano
Toraji Amano
Background/Aims: Delayed bleeding is among the adverse events associated with therapeutic gastrointestinal endoscopy. The aim of this study was to evaluate risk factors for delayed bleeding after gastrointestinal endoscopic resection in patients receiving oral anticoagulants as well as to compare the rates of occurrence of delayed bleeding between the oral anticoagulants used. Methods: We retrospectively analyzed a total of 772 patients receiving anticoagulants. Of these, 389 and 383 patients were receiving direct oral anticoagulants (DOACs) and warfarin, respectively. Therapeutic endoscopic procedures performed included endoscopic submucosal dissection (ESD), endoscopic mucosal resection, polypectomy, and cold polypectomy. Results: Delayed bleeding occurred in 90 patients (11.7%) with no significant difference between the DOAC and warfarin groups (9.5 and 13.8%, respectively). Delayed bleeding occurred significantly more frequently with apixaban than with rivaroxaban (13.5 vs. 6.4%; p < 0.05). A multivariate analysis identified continued anticoagulant therapy (OR 2.29), anticoagulant withdrawal with heparin bridging therapy (HBT; OR 2.18), anticoagulant therapy combined with 1 antiplatelet drug (OR 1.72), and ESD (OR 3.87) as risk factors for delayed bleeding. Conclusion: This study identified continued anticoagulant therapy, anticoagulant withdrawal with HBT, anticoagulant therapy combined with 1 antiplatelet drug, and ESD as risk factors for delayed bleeding after therapeutic endoscopy in patients receiving oral anticoagulants. Delayed bleeding rates were not significantly different between those receiving DOACs and warfarin. It was also suggested that the occurrence of delayed bleeding may vary between different DOACs and that oral anticoagulant withdrawal should be minimized during therapeutic gastrointestinal endoscopy, given the thromboembolic risk involved.

30 July 2024 in Clinical Endoscopy
Verified
Journal Article
Open access
PDF file
KKKimitoshi Kubo
Kimitoshi Kubo
NKNORIKO KIMURA
NORIKO KIMURA
MKMototsugu Kato
Mototsugu Kato
Since the introduction of vonoprazan, a potassium-competitive acid blocker (P-CAB), it has been demonstrated to reversibly inhibit gastric acid secretion by engaging in potassium-competitive ionic binding to H+/K+-ATPase. In contrast, proton pump inhibitors (PPIs) achieve H+/K+-ATPase inhibition through covalent binding to cysteine residues of the proton pump. Reported cases have indicated an emerging trend of P-CAB-related gastropathies, similar to those associated with PPIs, as well as unique gastropathies specific to P-CAB use, such as the identification of web-like mucus. Pathologically, parietal cell profusions, which show a positively correlated with hypergastrinemia, have a higher incidence in P-CAB users compared to PPI users. Thus, this review aims to summarize the endoscopic and pathological findings reported to date concerning P-CAB-related gastric mucosal lesions. Additionally, it seeks to discuss the differences between the PPIs and P-CABs in terms of the formation and frequency of associated gastropathies. This review highlights the evident differences in the mechanism of action and potency of acid inhibition between P-CABs and PPIs, notably contributing to differences in the formation and frequency of associated gastropathies. It emphasizes the necessity to distinguish between P-CAB-related and PPI-related gastropathies in the clinical setting.

15 February 2020 in Internal Medicine
Verified
Journal Article
Open access
PDF file
KKKimitoshi Kubo
Kimitoshi Kubo
NKNoriko Kimura
Noriko Kimura
SMSoichiro Matsuda
Soichiro Matsuda
MTMomoko Tsuda
Momoko Tsuda
KMKatsuhiro Mabe
Katsuhiro Mabe
MKMototsugu Kato
Mototsugu Kato
To date, no cases of vonoprazan-associated gastric mucosal redness have been reported, and its endoscopic and pathological features remain largely unclear. We report four cases of vonoprazan-associated gastric mucosal redness. In all cases, esophagogastroduodenoscopy (EGD) demonstrated linear or spotty redness that newly appeared in the greater curvature of the middle gastric body after the initiation of vonoprazan, which disappeared after its discontinuation. A tissue biopsy taken from the gastric mucosa with redness revealed inflammatory cell infiltration, parietal cell protrusions (PCPs), and oxyntic gland dilatation. To our knowledge, this is the first report describing the endoscopic and pathological features of vonoprazan-associated gastric mucosal redness.